Vanda Pharmaceuticals is hoping to try again with an amended trial after its experimental skin drug tradipitant failed a phase 3 test.
The drug was being assessed to see whether it could help pruritus (itching) in patients with in atopic dermatitis. In an update Tuesday, it seems it couldn’t: “The EPIONE study did not meet its primary endpoint in reduction of pruritus across the overall study population,” the biotech said in a statement.
